Cynthia Liu

Cynthia Liu

Auto-generated profile, based on publicly available information

Cynthia Liu

CAS, a division of the American Chemical Society, 2540 Olentangy River Road, Columbus, Ohio 43210-3012, United States

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2020 in ACS Central Science
Verified
Journal Article
Open access
CLCynthia Liu
Cynthia Liu
QZQiongqiong Zhou
Qiongqiong Zhou
YLYingzhu Li
Yingzhu Li
LGLinda V. Garner
Linda V. Garner
SWSteve P. Watkins
Steve P. Watkins
DADana Albaiu
Dana Albaiu

30 April 2020 in ACS Central Science
Verified
Journal Article
Closed access
LCLinda J. Carter
Linda J. Carter
LGLinda V. Garner
Linda V. Garner
JSJeffrey W. Smoot
Jeffrey W. Smoot
YLYingzhu Li
Yingzhu Li
QZQiongqiong Zhou
Qiongqiong Zhou
CLCynthia Liu
Cynthia Liu

29 March 2021 in ACS Central Science
Verified
Journal Article
Open access
YLYingzhu Li
Yingzhu Li
RTRumiana Tenchov
Rumiana Tenchov
JSJeffrey Smoot
Jeffrey Smoot
CLCynthia Liu
Cynthia Liu
SWSteven Watkins
Steven Watkins
QZQiongqiong Zhou
Qiongqiong Zhou
This report examines various vaccine platforms including inactivated vaccines, protein-based vaccines, viral vector vaccines, and nucleic acid (DNA or mRNA) vaccines, and their ways of producing immunogens in cells.

14 October 2020 in ACS Omega
Verified
Journal Article
Closed access
JIJulian Ivanov
Julian Ivanov
DPDmitrii Polshakov
Dmitrii Polshakov
JKJunko Kato-Weinstein
Junko Kato-Weinstein
QZQiongqiong Zhou
Qiongqiong Zhou
YLYingzhu Li
Yingzhu Li
CAChristopher Aultman
Christopher Aultman

3 July 2023 in ACS Pharmacology & Translational Science
Verified
Journal Article
Open access
DLDongqiao Li
Dongqiao Li
CLCynthia Liu
Cynthia Liu
YLYingzhu Li
Yingzhu Li
RTRumiana Tenchov
Rumiana Tenchov
JSJanet M. Sasso
Janet M. Sasso
QZQiongqiong Zhou
Qiongqiong Zhou
With the rapid success in the development of mRNA vaccines against COVID-19 and with a number of mRNA-based drugs ahead in the pipelines, mRNA has catapulted to the forefront of drug research, demonstrating its substantial effectiveness against a broad range of diseases. As the recent global pandemic gradually fades, we cannot stop thinking about what the world has gained: the realization and validation of the power of mRNA in modern medicine. A significant amount of research has now been concentrated on developing mRNA drugs and vaccine platforms against infectious and immune diseases, cancer, and other debilitating diseases and has demonstrated encouraging results. Here, based on the CAS Content Collection, we provide a landscape view of the current state, outline trends in the research and development of mRNA therapeutics and vaccines, and highlight some notable patents focusing on mRNA therapeutics, vaccines, and delivery systems. Analysis of diseases disclosed in patents also reveals highly investigated diseases for treatments with these medicines. Finally, we provide information about mRNA therapeutics and vaccines in clinical trials. We hope this Review will be useful for understanding the current knowledge in the field of mRNA medicines and will assist in efforts to solve its remaining challenges and revolutionize the treatment of human diseases.

13 November 2020
Verified
Conference Paper
Open access
AZAngela Zhou
Angela Zhou
CLCynthia Liu
Cynthia Liu
LGLinda Garner
Linda Garner
SWSteve Watkins
Steve Watkins
JSJeffery Smoot
Jeffery Smoot
DADana Albaiu
Dana Albaiu
Since the outbreak of the novel coronavirus disease COVID-19, caused by the SARS-CoV-2 virus, this disease has spread rapidly around the globe. Considering the devastating consequence of the pandemic, scientists and physicians have been racing to understand this new virus and pathophysiology of this disease to uncover possible treatment regimens and discover effective therapeutic